Stocks
Innate Immunotherapeutics LtdIIL
NASDAQHealthcareBiotechnology
A biotechnology company focused on developing immune‑modulating therapies for autoimmune diseases. Its primary asset, MIS416, has been studied as a potential treatment for progressive multiple sclerosis by targeting innate immune pathways. Investors have followed the company largely for the clinical...
52W Range: $0.03 – $0.05
Congressional Interest in Innate Immunotherapeutics Ltd (IIL)
No congressional trades have been disclosed for Innate Immunotherapeutics Ltd (IIL) yet. All data is sourced from STOCK Act periodic transaction reports filed with Congress.
Total Disclosures
0
Unique Politicians
0
Buys
0
Sells
0
Who in Congress Is Trading IIL?
No congressional trades found for this stock.